Published in J Neurol Neurosurg Psychiatry on February 01, 1994
Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry (2003) 1.58
Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry (1996) 1.04
Oxidative stress and cerebral endothelial cells: regulation of the blood-brain-barrier and antioxidant based interventions. Biochim Biophys Acta (2011) 0.98
Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery? J Neural Transm (Vienna) (2013) 0.84
The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry (2000) 0.81
Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease. J Neural Transm (Vienna) (1997) 0.81
Effects of 3-O-methyl on L-dopa-facilitated synthesis and efflux of dopamine from rat striatal slices. Br J Pharmacol (1995) 0.78
Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism. J Neural Transm (Vienna) (1997) 0.77
Parkinson's disease. Postgrad Med J (1997) 0.75
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry (1988) 14.72
Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiatry (1989) 3.53
Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet (1990) 2.30
Deprenyl in Parkinson's disease. Lancet (1977) 1.66
Expression of heat shock proteins in Alzheimer's disease. Neurology (1991) 1.35
Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients. Neurology (1987) 1.33
3-O-methyldopa uptake and inhibition of L-dopa at the blood-brain barrier. Life Sci (1975) 1.26
Pharmacokinetics of levodopa. Clin Neuropharmacol (1984) 1.24
Response to brief levodopa infusions in parkinsonian patients with and without motor fluctuations. Neurology (1988) 1.20
Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors. J Med Chem (1989) 1.12
Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat. Eur J Pharmacol (1988) 1.09
Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology (1983) 1.06
Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol Toxicol (1990) 1.04
Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol (1992) 1.03
Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations. Clin Neuropharmacol (1986) 1.00
Parkinsonism treated with 3-O-methyldopa. Clin Pharmacol Ther (1973) 0.98
New selective COMT inhibitors: useful adjuncts for Parkinson's disease? Trends Pharmacol Sci (1989) 0.96
Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res (1992) 0.96
Exercise hemodynamics and catecholamine metabolism after catechol-O-methyltransferase inhibition with nitecapone. Clin Pharmacol Ther (1990) 0.91
3-O-methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol (1987) 0.90
Catechol-O-methyltransferase activity in human and rat small intestine. Life Sci (1988) 0.87
3-O-Methyldopa, L-dopa, and trihexyphenidyl in the treatment of Parkinson's disease. Mayo Clin Proc (1973) 0.87
Computerized rotometer apparatus for recording circling behavior. Methods Find Exp Clin Pharmacol (1989) 0.86
Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers. Clin Neuropharmacol (1990) 0.85
Potentiation of the L-Dopa effect in man by the use of catechol-O-methyltransferase inhibitors. J Neurol Sci (1971) 0.84
Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease. Clin Neuropharmacol (1991) 0.81
Purification and properties of a catechol-o-methyltransferase of human liver. Eur J Biochem (1971) 0.81
3-O-methyldopa and motor fluctuations in Parkinson's disease. Neurology (1987) 0.78
[18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462). Neurology (1992) 0.78
Clinical significance of the relationship between O-methyldopa levels and levodopa intake. Neurology (1988) 0.77
Catechol-O-methyltransferase and Parkinson's disease. Adv Neurol (1984) 0.77
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry (1992) 33.67
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry (1988) 14.72
Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain (1991) 8.16
The surface glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties. J Virol (1999) 7.89
A film of patients with movement disorders made in Queen Square, London in the Mid-1920s by Samuel Alexander Kinnier Wilson. Mov Disord (2011) 6.45
What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology (1992) 6.03
Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proc Natl Acad Sci U S A (2000) 5.36
Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature (1981) 5.00
Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry (2000) 3.89
Striatonigral degeneration. A clinicopathological study. Brain (1990) 3.70
Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiatry (1989) 3.53
Neuropathological features of Alzheimer's disease in non-demented parkinsonian patients. J Neurol Neurosurg Psychiatry (1991) 3.38
Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology (2001) 3.25
The impact of treatment with levodopa on Parkinson's disease. Q J Med (1980) 3.14
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology (2008) 3.10
Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology (2011) 3.10
A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol (1993) 3.00
Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet (1988) 2.80
Cognitive deficits in the early stages of Parkinson's disease. Brain (1983) 2.65
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Regional brain and ventricular volumes in Tourette syndrome. Arch Gen Psychiatry (2001) 2.59
Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet (2005) 2.56
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52
PINK1 protein in normal human brain and Parkinson's disease. Brain (2006) 2.49
Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol (1990) 2.45
Geostatistical analysis of soil contamination in the Swiss Jura. Environ Pollut (1994) 2.45
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry (1997) 2.42
The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology (1997) 2.36
Molecular changes associated with the transmission of avian influenza a H5N1 and H9N2 viruses to humans. J Med Virol (2002) 2.35
Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet (1990) 2.30
Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl (1993) 2.27
Spinal internuncial neurones in progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry (1979) 2.20
Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology (2000) 2.19
Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol Neurosurg Psychiatry (1998) 2.19
Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem (1997) 2.10
Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord (2000) 2.10
Low-dose olanzapine for levodopa induced dyskinesias. Neurology (2000) 2.03
The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol (2012) 2.03
p38 Kinase-dependent MAPKAPK-2 activation functions as 3-phosphoinositide-dependent kinase-2 for Akt in human neutrophils. J Biol Chem (2000) 2.00
Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res Mol Brain Res (1995) 1.98
Multiple lineages of antigenically and genetically diverse influenza A virus co-circulate in the United States swine population. Virus Res (2004) 1.97
Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology (2001) 1.95
Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations. J Neurol Neurosurg Psychiatry (1989) 1.95
The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. Hum Mol Genet (2005) 1.94
A clinico-pathological study of subtypes in Parkinson's disease. Brain (2009) 1.91
Effect of Lactobacillus GG yoghurt in prevention of antibiotic associated diarrhoea. Ann Med (1990) 1.90
What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. 1992. Neurology (2001) 1.87
On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain (1984) 1.83
A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem (1997) 1.83
The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol Appl Neurobiol (1989) 1.79
Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease. Arch Neurol (1995) 1.79
Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology (2005) 1.77
Binomial cokriging for estimating and mapping the risk of childhood cancer. IMA J Math Appl Med Biol (1998) 1.77
Differences between influenza virus receptors on target cells of duck and chicken. Arch Virol (2002) 1.75
Acute movement disorders with bilateral basal ganglia lesions in uremia. Mov Disord (1998) 1.74
A clinical study of Gilles de la Tourette syndrome in the United Kingdom. J Neurol Neurosurg Psychiatry (1984) 1.72
Neurological deterioration in young adults with phenylketonuria. Lancet (1990) 1.71
Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry (1991) 1.69
Deprenyl in Parkinson's disease. Lancet (1977) 1.66
Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology (2003) 1.61
New pathologic observations in juvenile onset parkinsonism with dystonia. Neurology (1991) 1.57
A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology (1988) 1.57
Tau gene and Parkinson's disease: a case-control study and meta-analysis. J Neurol Neurosurg Psychiatry (2004) 1.56
The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology (1986) 1.55
Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry (1990) 1.54
Cerebral tuberculomas developing during treatment of tuberculous meningitis. Lancet (1980) 1.51
Tourette's syndrome: a cross sectional study to examine the PANDAS hypothesis. J Neurol Neurosurg Psychiatry (2003) 1.51
Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry (1990) 1.50
Incidental Lewy body disease in black Africans. Lancet (1994) 1.50
Alpha-tocopherol levels in brain are not altered in Parkinson's disease. Ann Neurol (1992) 1.49
Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J Neurol Neurosurg Psychiatry (2006) 1.48
Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology (1999) 1.46
The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain (2001) 1.44
Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia). Brain (1987) 1.44
Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry (2004) 1.44
Bradyphrenia in Parkinson's disease and psychomotor retardation in depressive illness. An experimental study. Brain (1987) 1.44
Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol (1992) 1.43
Patterns of regional cerebral blood flow in corticobasal degeneration studied using HMPAO SPECT; comparison with Parkinson's disease and normal controls. Mov Disord (1995) 1.43
Idiopathic Parkinson's disease combined with multiple system atrophy. A clinicopathological report. Mov Disord (1991) 1.42
Parkinsonism following electrical injury to the hand. Mov Disord (1998) 1.42
Multicenter study of oxygen-insensitive handheld glucose point-of-care testing in critical care/hospital/ambulatory patients in the United States and Canada. Crit Care Med (1998) 1.39
Transplantation in Parkinson's disease. Br J Hosp Med (1989) 1.39
Increased nigral iron content in postmortem parkinsonian brain. Lancet (1987) 1.39
The psychopathology of the Gilles de la Tourette syndrome. A phenomenological analysis. Br J Psychiatry (1988) 1.39
Sign language tics in a prelingually deaf man. Mov Disord (2000) 1.38
Anti-basal ganglia antibodies in acute and persistent Sydenham's chorea. Neurology (2002) 1.38
Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol (1994) 1.36
Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology (2003) 1.35
Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol (1978) 1.35
Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy. Neurology (2005) 1.33
Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain (2008) 1.32
Neuronal filaments in Alzheimer's, Pick's, and Parkinson's diseases. N Engl J Med (1985) 1.32
Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study. J Neurol Neurosurg Psychiatry (2006) 1.31
Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology (1994) 1.30
"Off period" dystonia and "on period" choreoathetosis in levodopa-treated patients with Parkinson's disease. Lancet (1977) 1.30
Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord (1993) 1.30